Royal Bank Of Canada Immuno Gen, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $423,278 - $1.02 Million	33,971 Added 78.38%	77,312 $2.29 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $302,230 - $426,211	21,450 Added 97.99%	43,341 $687,000
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $153,903 - $822,872	-41,041 Reduced 65.21%	21,891 $413,000
Q1 2023 May 15, 2023	SELL	$3.67 - $4.92 $183,778 - $246,373	-50,076 Reduced 44.31%	62,932 $241,000
Q4 2022 Feb 14, 2023	SELL	$4.55 - $6.31 $21,485 - $29,795	-4,722 Reduced 4.01%	113,008 $560,000
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $72,240 - $104,328	16,125 Added 15.87%	117,730 $563,000
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $72,339 - $132,278	-22,965 Reduced 18.44%	101,605 $457,000
Q1 2022 May 16, 2022	SELL	$4.26 - $7.48 $134,748 - $236,599	-31,631 Reduced 20.25%	124,570 $593,000
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $77,966 - $123,105	16,414 Added 11.74%	156,201 $1.16 Million
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $35,330 - $46,380	7,038 Added 5.3%	139,787 $794,000
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $768,616 - $1.14 Million	132,749 New	132,749 $874,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.